Aurinia Pharmaceuticals Inc

AUPH XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

Short interest (May 15)

7.0%

Net Short (Jun 03 ): 0.2%

Borrow Fee

0.27%

↓ 5.3%

Available Shares

↓ 18.2%

Price Chart

Company Overview

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001600620

Asset Type: CS

Market Data

Market Cap: $1,979,179,716

Employees: 128

Status: Active

Short Interest

Current Borrow Fee 0.27%

Range: 0.27% - 0.27%

Available Shares 2M

Range: 1.4M - 1.7M

Recent Changes

Fee Change: ↓ 0.0%

Available Change: ↓ 10.8%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime